These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 25829020)
1. High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC. Xu YF; Lu Y; Cheng H; Jiang J; Xu J; Long J; Liu L; Ni Q; Liu C; Yu XJ Curr Mol Med; 2015; 15(4):360-7. PubMed ID: 25829020 [TBL] [Abstract][Full Text] [Related]
2. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519 [TBL] [Abstract][Full Text] [Related]
3. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054 [TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8 Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962 [TBL] [Abstract][Full Text] [Related]
5. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma. Yuan Y; Yang Z; Miao X; Li D; Liu Z; Zou Q Tumour Biol; 2015 Dec; 36(12):9961-8. PubMed ID: 26178481 [TBL] [Abstract][Full Text] [Related]
6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
7. High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Gong C; Zhang Y; Chen Y; Zhang H; Liu X; Xue H; Ji L; Wang L; Yang L; Zhou G; Wan C Tumour Biol; 2015 Dec; 36(12):9189-99. PubMed ID: 26088450 [TBL] [Abstract][Full Text] [Related]
8. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma. Liu QH; Shi ML; Bai J; Zheng JN Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353 [TBL] [Abstract][Full Text] [Related]
9. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival. Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488 [TBL] [Abstract][Full Text] [Related]
10. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma. Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693 [TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma]. Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220 [TBL] [Abstract][Full Text] [Related]
13. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Yang J; Jiang Y; He R; Liu W; Yang M; Tao L; Fu X; Shen Y; Li J; Liu D; Huo Y; Zhang J; Hua R; Zhang Z; Sun Y J Immunol Res; 2019; 2019():8656282. PubMed ID: 31583260 [TBL] [Abstract][Full Text] [Related]
14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393 [TBL] [Abstract][Full Text] [Related]
15. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504 [TBL] [Abstract][Full Text] [Related]
16. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma. Guo XB; Yin HS; Wang JY Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5892-5898. PubMed ID: 30280769 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review. Ding Y; Du Y Int J Surg; 2019 May; 65():32-38. PubMed ID: 30902754 [TBL] [Abstract][Full Text] [Related]
18. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880 [TBL] [Abstract][Full Text] [Related]
19. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Luchini C; Cros J; Pea A; Pilati C; Veronese N; Rusev B; Capelli P; Mafficini A; Nottegar A; Brosens LAA; Noë M; Offerhaus GJA; Chianchiano P; Riva G; Piccoli P; Parolini C; Malleo G; Lawlor RT; Corbo V; Sperandio N; Barbareschi M; Fassan M; Cheng L; Wood LD; Scarpa A Hum Pathol; 2018 Nov; 81():157-165. PubMed ID: 30031096 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]